Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 10,397 |
|
|||||
| News | - | ||||||
| Day High | 3.71 | Low High |
|||||
| Day Low | 3.2125 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| GT Biopharma Inc | GTBP | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.4066 | -10.84% | 3.345 | 23:00:06 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.71 | 3.2125 | 3.71 | 3.345 | 3.7516 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 123 | 10,397 | US$ 3.39 | US$ 35,240 | - | 3.2125 - 16.11 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:23:36 | 21 | US$ 3.25 | USD |
GT Biopharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 4.61M | 1.38M | - | 0 | -7.6M | -5.50 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
GT Biopharma News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/14/2024 | 13:46 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 2/01/2024 | 11:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/21/2023 | 14:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/04/2023 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/06/2023 | 16:25 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 11/06/2023 | 16:23 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 11/06/2023 | 16:21 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 11/01/2023 | 08:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 10/27/2023 | 16:23 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
| 9/19/2023 | 10:56 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 8/22/2023 | 15:55 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/15/2023 | 18:29 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GTBP Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.80 | 3.88 | 3.2125 | 3.69 | 4,717 | -0.455 | -11.97% |
| 1 Month | 4.58 | 4.77 | 3.2125 | 4.03 | 6,931 | -1.24 | -26.97% |
| 3 Months | 5.538 | 6.00 | 3.2125 | 4.80 | 19,203 | -2.19 | -39.60% |
| 6 Months | 7.35 | 9.90 | 3.2125 | 6.88 | 86,270 | -4.01 | -54.49% |
| 1 Year | 10.50 | 16.11 | 3.2125 | 8.62 | 227,295 | -7.16 | -68.14% |
| 3 Years | 345.90 | 591.993 | 3.2125 | 140.34 | 215,904 | -342.56 | -99.03% |
| 5 Years | 165.00 | 591.993 | 3.2125 | 154.35 | 245,191 | -161.66 | -97.97% |
GT Biopharma Description
| GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. |
